Bifidobacterium infantis and Reduced Gastrointestinal Inflammation

• Clinical benefits of Bifidobacterium infantis YLGB-1496 in modulating gut microbiota and immunity in young children.

  • 2026-01-05
  • Clinical Trial
  • Frontiers in nutrition 12
  • • Mageswaran Uma Mageswary
    • Pin Li
    • Rocky Vester Richmond
    • Yusof Azianey
    • Intan Juliana Abd Hamid
    • Fahisham Taib
    • Min-Tze Liong
    • Adli Ali
    • Joo Shun Tan
    • Yumei Zhang

  • PubMed: 41561177
  • DOI: 10.3389/fnut.2025.1713135

  5 Insights on

  • Reduced Gastrointestinal Inflammation

  • Moderate evidence

  the probiotic group exhibited a favorable anti-inflammatory profile with reduced levels of fecal IFN-γ, IL-1β, and calprotectin, and a trend toward increased fecal IgA over time as compared to the placebo group.

  Effect

  Beneficial

  Effect size

  Moderate